S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Strategic Gold Play You Haven't Heard About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Strategic Gold Play You Haven't Heard About (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Strategic Gold Play You Haven't Heard About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Strategic Gold Play You Haven't Heard About (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Strategic Gold Play You Haven't Heard About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Strategic Gold Play You Haven't Heard About (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Strategic Gold Play You Haven't Heard About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Strategic Gold Play You Haven't Heard About (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company

Fulgent Genetics Stock Price, News & Analysis (NASDAQ:FLGT)

$25.95
-1.52 (-5.53%)
(As of 12/5/2023 ET)
Compare
Today's Range
$25.91
$27.28
50-Day Range
$23.64
$27.93
52-Week Range
$23.09
$44.09
Volume
234,830 shs
Average Volume
220,270 shs
Market Capitalization
$768.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.50

Fulgent Genetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
40.7% Upside
$36.50 Price Target
Short Interest
Bearish
4.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.84mentions of Fulgent Genetics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$159,241 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.09) to ($1.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

213th out of 948 stocks

Diagnostics & Research Industry

4th out of 5 stocks


FLGT stock logo

About Fulgent Genetics Stock (NASDAQ:FLGT)

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

FLGT Stock Price History

FLGT Stock News Headlines

Following Up On Fulgent Genetics
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Q3 2023 Fulgent Genetics Inc Earnings Call
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Fulgent Genetics Reports Loss In Q3 On Lower Revenue
Fulgent Reports Third Quarter 2023 Financial Results
Top 20 Genomics Companies in the World
Q2 2023 Fulgent Genetics Inc Earnings Call
Fulgent Reports Second Quarter 2023 Financial Results
Fulgent Genetics Q2 2023 Earnings Preview
See More Headlines
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FLGT
Employees
1,012
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$36.50
High Stock Price Target
$45.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+40.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$143.40 million
Pretax Margin
-21.77%

Debt

Sales & Book Value

Annual Sales
$618.97 million
Cash Flow
$6.21 per share
Book Value
$43.14 per share

Miscellaneous

Free Float
20,222,000
Market Cap
$768.90 million
Optionable
Not Optionable
Beta
1.56

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives















FLGT Stock Analysis - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FLGT shares.
View FLGT analyst ratings
or view top-rated stocks.

What is Fulgent Genetics' stock price target for 2024?

2 equities research analysts have issued 12 month price targets for Fulgent Genetics' stock. Their FLGT share price targets range from $28.00 to $45.00. On average, they predict the company's share price to reach $36.50 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price.
View analysts price targets for FLGT
or view top-rated stocks among Wall Street analysts.

How have FLGT shares performed in 2023?

Fulgent Genetics' stock was trading at $29.78 on January 1st, 2023. Since then, FLGT shares have decreased by 12.9% and is now trading at $25.95.
View the best growth stocks for 2023 here
.

When is Fulgent Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our FLGT earnings forecast
.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) released its quarterly earnings data on Friday, November, 3rd. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.07. The firm had revenue of $84.70 million for the quarter, compared to analyst estimates of $64.42 million. Fulgent Genetics had a negative net margin of 22.17% and a negative trailing twelve-month return on equity of 4.59%. The business's revenue for the quarter was down 19.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.11 EPS.

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its FY23 earnings guidance on Friday, November, 3rd. The company provided earnings per share (EPS) guidance of ($0.95) for the period, compared to the consensus EPS estimate of ($0.95).

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Invesco Ltd. (1.06%), American Century Companies Inc. (0.86%), Charles Schwab Investment Management Inc. (0.79%), Northern Trust Corp (0.76%), Bank of New York Mellon Corp (0.71%) and Principal Financial Group Inc. (0.39%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends
.

How do I buy shares of Fulgent Genetics?

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Fulgent Genetics have any subsidiaries?
The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More
This page (NASDAQ:FLGT) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -